Drug Type Small molecule drug |
Synonyms BI 1358894, BI1358894 |
Target |
Mechanism TRPC4 inhibitors(Short transient receptor potential channel 4 inhibitors), TRPC5 inhibitors(Short transient receptor potential channel 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stress Disorders, Post-Traumatic | Phase 2 | US | 07 Dec 2021 | |
Stress Disorders, Post-Traumatic | Phase 2 | HR | 07 Dec 2021 | |
Stress Disorders, Post-Traumatic | Phase 2 | FI | 07 Dec 2021 | |
Stress Disorders, Post-Traumatic | Phase 2 | DE | 07 Dec 2021 | |
Stress Disorders, Post-Traumatic | Phase 2 | IL | 07 Dec 2021 | |
Stress Disorders, Post-Traumatic | Phase 2 | MX | 07 Dec 2021 | |
Stress Disorders, Post-Traumatic | Phase 2 | PL | 07 Dec 2021 | |
Stress Disorders, Post-Traumatic | Phase 2 | SE | 07 Dec 2021 | |
Borderline Personality Disorder | Phase 2 | US | 13 Nov 2020 | |
Borderline Personality Disorder | Phase 2 | JP | 13 Nov 2020 |
Phase 2 | 390 | Placebo (Placebo) | fvbfxmexas(ookztcesmi) = qkucjomksi wiywxscblr (atdfcrfxet, qyfnucpeso - mcxjtxkprr) View more | - | 30 Jan 2024 | ||
(BI 1358894 5mg) | fvbfxmexas(ookztcesmi) = sfmxabukjl wiywxscblr (atdfcrfxet, vlhvfdwoxb - nllmxmrswc) View more | ||||||
Phase 2 | 45 | (BI 1358894) | fnlwctihum(kruclonxpg) = qwggldpvcd zqryayviky (dkmaokrnvm, yycchitykw - llyoptrvgt) View more | - | 11 May 2023 | ||
Placebo (Placebo) | fnlwctihum(kruclonxpg) = davxaxupsg zqryayviky (dkmaokrnvm, itujjsroih - mqbvztisxz) View more |